A multicenter comparative acute myeloid leukemia study: can we explain the differences in the outcomes in resource-constrained settings?

References

• Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136–1152.
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Derolf AR, Edgren G, et al. Socioeconomic differences in patient survival are increasing for acute myeloid leukemia and multiple myeloma in Sweden. J Clin Oncol. 2009;27(12):2073–2080.
   PubMed Web of Science ®Google Scholar
• Rodriguez CP, Baz R, Jawde RA, et al. Impact of socioeconomic status and distance from treatment center on survival in patients receiving remission induction therapy for newly diagnosed acute myeloid leukemia. Leuk Res. 2008;32(3):413–420.
   PubMed Web of Science ®Google Scholar
• The World Bank Group. Low & middle income [Internet]; 2019; [cited 2019 Nov 14]. Available from: data.worldbank.org/income-level/low-and-middle-income
   Google Scholar
• Fagundes EM, Rocha V, Glória ABF, et al. De novo acute myeloid leukemia in adults younger than 60 years of age: socioeconomic aspects and treatment results in a Brazilian university center. Leuk Lymphoma. 2006;47(8):1557–1564.
   PubMed Web of Science ®Google Scholar
• Giebel S, Labopin M, Ehninger G, et al. Association of Human Development Index with rates and outcomes of hematopoietic stem cell transplantation for patients with acute leukemia. Blood. 2010;116(1):122–128.
   PubMed Web of Science ®Google Scholar
• Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood. 2016;127(1):62–70.
   PubMed Web of Science ®Google Scholar
• Uyl-de Groot CA, Gelderblom-den Hartog J, Huijgens PC, et al. Costs of diagnosis, treatment, and follow up of patients with acute myeloid leukemia in the Netherlands. J Hematother Stem Cell Res. 2001;10(1):187–192.
   PubMedGoogle Scholar
• Benicio MTdL, Ribeiro AFT, Américo AD, et al. Evaluation of the European LeukemiaNet recommendations for predicting outcomes of patients with acute myeloid leukemia treated in low- and middle-income countries (LMIC): a Brazilian experience. Leuk Res. 2017;60:109–114.
   PubMed Web of Science ®Google Scholar
• Bertoli S, Tavitian S, Huynh A, et al. Improved outcome for AML patients over the years 2000–2014. Blood Cancer J. 2017;7(12):635.
   PubMed Web of Science ®Google Scholar
• Stalfelt AM, Brodin H, Pettersson S, et al. The final phase in acute myeloid leukaemia (AML): a study of cause of death, place of death and type of care during the last week of life. Leuk Res. 2001;25(8):673–680.
   PubMed Web of Science ®Google Scholar
• Percival M-EM, Tao L, Medeiros BC, et al. Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: a SEER database analysis. Cancer. 2015;121(12):2004–2012.
   PubMed Web of Science ®Google Scholar
• da Silva WF Jr, Rosa LI, da Marquez GL, et al. Real-life outcomes on acute promyelocytic leukemia in Brazil – early deaths are still a problem. Clin Lymphoma Myeloma Leuk. 2019;19(2):e116–e122.
   PubMed Web of Science ®Google Scholar
• Nganthavee V, Phutthasakda W, Atipas K, et al. High incidence of invasive fungal infection during acute myeloid leukemia treatment in a resource-limited country: clinical risk factors and treatment outcomes. Support Care Cancer. 2019;27(9):3613–3622.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
   PubMed Web of Science ®Google Scholar
• Ruhnke M, Schwartz S. Recent developments in the management of invasive fungal infections in patients with oncohematological diseases. Ther Adv Hematol. 2016;7(6):345–359.
   PubMed Web of Science ®Google Scholar
• Magiorakos A-P, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281.
   PubMed Web of Science ®Google Scholar
• Kiyoi H, Naoe T, Yokota S, et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia. 1997;11(9):1447–1452.
   PubMed Web of Science ®Google Scholar
• Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352(3):254–266.
   PubMed Web of Science ®Google Scholar
• Wouters BJ, Löwenberg B, Erpelinck-Verschueren CAJ, et al. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood. 2009;113(13):3088–3091.
   PubMed Web of Science ®Google Scholar
• Silveira DRA, Quek L, Santos IS, et al. Integrating clinical features with genetic factors enhances survival prediction for adults with acute myeloid leukemia. Blood Adv. 2020;4(10):2339–2350.
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
   PubMed Web of Science ®Google Scholar
• Ho G, Wun T, Muffly L, et al. Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute-designated cancer centers in California. Cancer. 2018;124(9):1938–1945.
   PubMed Web of Science ®Google Scholar
• Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr. 1974;19(6):716–723.
   Web of Science ®Google Scholar
• Gafter-Gvili A, Fraser A, Paul M, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev. 2012;1:CD004386.
   PubMedGoogle Scholar
• Ferreira AM, Moreira F, Guimaraes T, et al. Epidemiology, risk factors and outcomes of multi-drug-resistant bloodstream infections in haematopoietic stem cell transplant recipients: importance of previous gut colonization. J Hosp Infect. 2018;100(1):83–91.
   PubMed Web of Science ®Google Scholar
• de Maio Carrilho CMD, de Oliveira LM, Gaudereto J, et al. A prospective study of treatment of carbapenem-resistant Enterobacteriaceae infections and risk factors associated with outcome. BMC Infect Dis. 2016;16(1):629.
   PubMedGoogle Scholar
• Halpern AB, Lyman GH, Walsh TJ, et al. Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia. Blood. 2015;126(26):2790–2797.
   PubMed Web of Science ®Google Scholar
• Nucci M, Garnica M, Gloria AB, et al. Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil. Clin Microbiol Infect. 2013;19(8):745–751.
   PubMed Web of Science ®Google Scholar
• Loke J, Malladi R, Moss P, et al. The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience. Br J Haematol. 2020;188(1):129–146.
   PubMed Web of Science ®Google Scholar
• Silva WF, da Rosa LI, da Seguro FS, et al. Salvage treatment for refractory or relapsed acute myeloid leukemia: a 10-year single-center experience. Clinics. 2020;75:e1566.
   PubMed Web of Science ®Google Scholar
• Niederwieser D, Baldomero H, Szer J, et al. Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. Bone Marrow Transplant. 2016;51(6):778–785.
   PubMed Web of Science ®Google Scholar
• Majhail NS, Nayyar S, Santibañez MEB, et al. Racial disparities in hematopoietic cell transplantation in the United States. Bone Marrow Transplant. 2012;47(11):1385–1390.
   PubMed Web of Science ®Google Scholar
• Patel MI, Ma Y, Mitchell B, et al. How do differences in treatment impact racial and ethnic disparities in acute myeloid leukemia? Cancer Epidemiol Biomarkers Prev. 2015;24(2):344–349.
   PubMed Web of Science ®Google Scholar
• Jabo B, Morgan JW, Martinez ME, et al. Sociodemographic disparities in chemotherapy and hematopoietic cell transplantation utilization among adult acute lymphoblastic and acute myeloid leukemia patients. PLoS One. 2017;12(4):e0174760.
   PubMed Web of Science ®Google Scholar
• Rashidi A, Hamadani M, Zhang M-J, et al. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Blood Adv. 2019;3(12):1826–1836.
   PubMed Web of Science ®Google Scholar